Skip to main content
TOPICS
Videos
Provider
Payer
Pharma
Consumer
Investor
RESOURCES
Events
Jobs
Learning Center
Webinars
White Papers
REGIONS
ANZ
ASIA
EMEA
Global Edition
MORE
About
Advertise
Contact
Privacy Policy
ANZ
ASIA
EMEA
Global Edition
Weill Cornell Medicine
Akili to study EndeavorRx as a COVID-19 brain fog treatment
By
Mallory Hackett
|
11:41 am |
April 09, 2021
The digital therapeutic is designed to treat children ages 8 to 12 with ADHD, but the two studies announced this week will focus on an adult population.
